Outcome of transfusion of K:11 erythrocytes in a patient with anti-K11 antibody.
OBJECTIVE
The clinical significance of anti-K11 in red cell transfusion therapy is unknown. We report the outcome of transfusion of K:11 erythrocytes into a patient with a known anti-K11 antibody.


METHODS
The patient was monitored clinically following transfusion of 11 units of K:11 erythrocytes. A red cell survival study with K:11 erythrocytes and a monocyte monolayer assay (MMA) were performed.


RESULTS
No adverse clinical outcome was detected. The red cell survival study showed normal survival of K:11 erythrocytes, and the MMA showed no increase in reactive monocytes.


CONCLUSIONS
These findings suggest that K:11 red cells can safely be transfused to individuals with anti-K11 antibody.
Kelley
C M
CM
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA.
Karwal
M W
MW
Schlueter
A J
AJ
Olson
J D
JD
D000328:Adult; D000740:Anemia / Q000209:etiology / Q000628:therapy; D001787:Blood Group Incompatibility / Q000276:immunology*; D004381:Duodenal Ulcer / Q000150:complications / Q000601:surgery; D004905:Erythrocyte Aging; D017707:Erythrocyte Transfusion; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D007626:Kell Blood-Group System / Q000276:immunology*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy; D010439:Peptic Ulcer Perforation / Q000150:complications / Q000601:surgery; D011183:Postoperative Complications / Q000628:therapy; D006435:Renal Dialysis
D007518:Isoantibodies; D007626:Kell Blood-Group System